Drug intelligence / Profile preview

RO5095932

Development stage: Phase 1
Lead developer: Roche
Modality: Small Molecules
Administration: Subcutaneous

Overview

RO5095932 is a small molecule drug developed by F. Hoffmann-La Roche for the treatment of type 2 diabetes mellitus. It was investigated as a subcutaneous therapy in adult patients with type 2 diabetes who were on stable metformin therapy. The drug underwent phase 1 clinical trials to assess its safety, tolerability, pharmacokinetics, and pharmacodynamics when administered as single or escalating doses. No approved indications or detailed mechanism of action have been disclosed publicly[1][2][3].

Beyond the preview

Go deeper on RO5095932.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RO5095932.

Explore the full profile